Shekher Bose on AstraZeneca’s Voluntary Withdrawal of Andexxa
Shekher Bose, Client Partner at Beyondsight Intelligence, reposted Beyondsight Intelligence on LinkedIn:
”This marks the end of availability for the only specific reversal agent for apixaban and rivaroxaban in the U.S., shifting reliance back to non-specific options like PCCs or supportive care for managing FXa inhibitor-associated bleeds.”
Qutoing Beyondsight Intelligence‘s post:
”FDA Issues Safety Update on Andexxa — U.S. Withdrawal Announced
The FDA has determined that postmarketing safety data for Andexxa (andexanet alfa), the anticoagulation reversal agent, show that serious thromboembolic risks outweigh its clinical benefits.
AstraZeneca will voluntarily withdraw Andexxa from the U.S. market, with availability ending December 22, 2025.
Key Points:
• Granted accelerated approval in 2018 for reversal of rivaroxaban and apixaban in life-threatening or uncontrolled bleeding
• Approval included a Boxed Warning for thromboembolic risk
• Postmarketing evidence, including ANNEXA-I, raised concerns around thrombotic events and mortality
Why It Matters:
• Highlights how real-world and confirmatory data can fundamentally shift benefit–risk assessments
• Reinforces the FDA’s scrutiny of accelerated approvals when safety signals emerge
• Leaves a gap in anticoagulation reversal options, impacting critical care decision-making
Key Takeaway:
Andexxa’s U.S. withdrawal underscores the power of post-approval evidence in reshaping regulatory outcomes—and the importance of long-term safety surveillance for high-risk biologics.
Follow our page for more such updates.
News Source.”
Stay updated with Hemostasis Today.
-
Feb 5, 2026, 17:35Shiny K. Kajal: ELISA vs CLIA vs NAT – Comparison of Screening Test for TTis
-
Feb 5, 2026, 17:31Bartosz Hudzik: Top 10 Advances in Thrombosis and Antithrombotic Therapy in 2025
-
Feb 5, 2026, 17:27Jecko Thachil: A Historical Perspective on Iron Deficiency Anaemia in Women
-
Feb 5, 2026, 17:20Melanie Daniel: A Landmark Session on Hemophilia and Rare Bleeding Disorders at the National Academy of Medicine
-
Feb 5, 2026, 17:14WFH Annual Global Survey Identifies Over 112,000 Women and Girls With Bleeding Disorders
-
Feb 5, 2026, 16:22Muthukumar R: What if One Blood Test Could Tell Doctors Much More Than it Does Today?
-
Feb 5, 2026, 16:20Emmanuel J Favaloro: New Study on Biomarkers for Coagulation Disorders
-
Feb 5, 2026, 16:18Maxime Dely: Trends in Red Blood Cell Consumption in France
-
Feb 5, 2026, 16:17Shervin Jose: How Herbal Medicine Changed World History